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Novel strategies are required to selectively
sensitize tumour cells to radiation-induced DNA
damage1. The G2 cell cycle checkpoint is an
attractive target for this, as normal cells will be
protected by their intact G1 checkpoint, which is
lost in the majority of cancer cells. ATR is an
important mediator of the G2 checkpoint.
Preclinical data suggest that ATR inhibition will
sensitise to DNA damaging therapies, including
The study comprises three parts (fig. 3): parts A and B will assess AZD6738 as a single
agent in dose escalation to MTD (part A), followed by expansion cohorts enriched for
defective DNA damage response (part B). Part C will assess AZD6738 in combination with
palliative RT in which participants will receive 20 Gy in 10 fractions, with per cohort
escalation of drug dose to monotherapy MTD if tolerated. At the highest tolerated
combination dose, the RT dose will be escalated to 30 Gy in 15 fractions. Maintenance
AZD6738 post-RT will be tested at the highest tolerated combination dose.
Numerous potential predictive biomarkers for ATR inhibitors have been
suggested, including loss of DDR components, loss of ATM, oncogene
activation, and high levels of replication stress. Fresh biopsy will be
mandatory for participants entering the expansion phase.
The study opened in August 2014. The study is dose escalating in part A and part C has
opened and treated its first patient. Part B will open when dose escalation has completed.
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RT2,3 (fig. 2). Single-agent activity in cancer cell lines has
also been demonstrated3 (fig.1), with pre-clinical data
suggesting a number of potential factors which may
sensitise to ATR inhibition.
This multi-part phase 1 trial aims to assess safety and
tolerability and preliminary anti-tumour activity of the ATR
inhibitor AZD67384 as monotherapy and in combination
References
1. J Clin Oncol 2015. 33(29):3251-61
2. Clin Oncol (R Coll Radiol) 2014. 26(5):257-65
3. Dillon, Barker et al. Submitted 2016
4. Future Med Chem 2015. 7(7): 873-91
Key Inclusion criteria Key Exclusion criteria
1. Advanced solid tumour
1. Therapy with any other investigational medical product 
concurrently or within 28 days
2. Documented disease progression prior to study entry and 
measurable disease (Part B only)
2. Investigational medicinal products, endocrine therapy, 
immunotherapy or chemotherapy during the previous four 
weeks before treatment.
3. Presence of putative markers of sensitivity to AZD6738 
defined on analysis of tumour material (part B only).
3. Receiving, or having received, concomitant medications, 
herbal supplements and/or foods that significantly modulate 
CYP3A4 or P-gp activity
4. Age must be 18 years or over 4. Pregnant or breast-feeding women.  
5. All acute toxic effects of any prior chemotherapy or surgical 
procedures must have resolved to CTCAE4 Grade ≤1. Surgery 
must have occurred at least 14 days prior to study enrolment.
5. Male patients with partners of child-bearing potential 
(unless they agree to use highly effective contraception 
during the trial and for six months afterwards).  
6. ECOG performance status 0-1 (part A); 0-2 (parts B and C) 6. Ability to become pregnant (or already pregnant or 
lactating)
7. Life expectancy of at least 3 months.
7. Clinically significant cardiac disease
8. Normal organ and bone marrow function measured within 7 
days prior to administration of study treatment 8. Known HIV positive or active hepatitis B or C infection
9. Signed informed consent
9. Uncontrolled active infection
10. Part B only: tumour site amenable to fresh biopsy (clinical 
or radiologically-guided)
10. Symptomatic and progressive or steroid-requiring brain 
metastases or leptomeningeal disease involvement.
11. Symptomatic disease or disease that is likely to cause 
symptoms within a short period of time such that palliative 
radiotherapy is indicated or justified (Part C only).
11. Relative hypotension (<100/60mmHg) or clinically 
relevant orthostatic hypotension, including a fall in blood 
pressure of >20mmHg
12. Prior radiotherapy to the treatment site (Part C only).
with palliative RT, escalating both drug and radiation
dose at a dose-fractionation relevant to radical
treatment. The design aims to test a novel agent at the
earliest stage of clinical development and assess safety
in combination with RT, with the aim of moving to a
radically-treated population if tolerated.
Objectives
Fig. 1: sensitivity of a panel of 
cancer cell lines to AZD6738 
(viability assay, 72 h MTT)
Fig. 2: radiosensitization by AZD6738, 
irrespective of p53 status, HCT116 cells.  
Clonogenic assay.  *: p<0.05
Primary objectives
Feasibility and safety of administration of single-agent AZD6738 in patients with solid tumours
and in combination with radiotherapy in patients with solid tumours during different schedules
of fractionated palliative radiotherapy.
Secondary objectives
Guide dose and schedule selection for subsequent studies of AZD6738 as a single-agent or
with palliative or radical radiotherapy.
Preliminary anti-tumour activity.
DDR defect
Replication 
stressATM loss
Fig. 3: Study design
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Patients will be stratified according to the presence of impaired
DNA damage response (DDR), assessed using whole-exome
sequencing; high levels of replication stress, measured using
immunohistochemical (IHC) markers; and loss of ATM expression
on IHC. A group of participants without any of these characteristics
will also be assessed.
